Key Points {#FPar1}
==========

We narratively reviewed 32 systematically identified, controlled studies that assessed interventions designed to improve adherence to statins.Absolute increases in mean adherence to statins were modest (+7 to +22 %) for successful interventions that used comparable adherence measures (medication possession ratio, proportion of days covered, or similar). Nevertheless, increased adherence to statins generally also improved cholesterol measures.Cognitive education delivered face-to-face multiple times was the most consistent feature of successful interventions, although successful examples of other intervention types (e.g. behavioural counselling), were also found.Most interventions that improve adherence to statins are resource intensive, despite only having modest effects. Mobile health platforms may be a more efficient alternative, but have not been well explored in relation to statin use.

Introduction {#Sec1}
============

Hypercholesterolemia is one of the main modifiable risk factors for cardiovascular disease (CVD) \[[@CR1], [@CR2]\]. There is compelling evidence that statins are effective at reducing lipid levels, the risk of CVD events and mortality \[[@CR3], [@CR4]\]. Concordantly, poor adherence to statins has been shown to increase the risk of CVD morbidity and death \[[@CR5]--[@CR7]\]. Nonadherence to statins has been estimated to be about 50 % over 5 years, with the highest rates of discontinuation observed during the first year of treatment \[[@CR8]--[@CR10]\]. Poor adherence to medication is the result of complex interactions between patient- physician- and healthcare-related factors \[[@CR11]\]. Patient-reported reasons for reduced adherence to statins include insufficient knowledge of their benefits (e.g. the belief that statins are unnecessary for good health) uncertainty over whether treatment should be continued because of a lack of follow-up by clinicians, distrust of clinicians' instructions, concerns about the short- and long-term risks of taking statins, preferences for alternative treatment such as herbal remedies, and the inconvenience of taking lipid-lowering medications \[e.g. requirement for laboratory testing, complicated dosing regimens---especially when patients are taking many different (not necessarily all CVD-related) medications\] \[[@CR11]--[@CR14]\]. Age (usually \<50 years and ≥70 years), female sex, lower income and use in primary prevention (relative to secondary prevention) are also associated with nonadherence to statins \[[@CR15]\]. Interventions to enhance adherence to statins are warranted to improve health outcomes and decrease medical costs. A number of high-quality reviews have attempted to assess the impact of interventions on adherence to medication in general \[[@CR16]--[@CR18]\], but none (to our knowledge) have focused specifically on statins. The main objectives of this narrative review were therefore to undertake a systematic search for studies assessing the impact of patient-centered interventions on adherence to statins, systematically categorize interventions according to their component parts, and then attempt to determine which intervention components are the most effective.

Methods {#Sec2}
=======

Systematic Searches {#Sec3}
-------------------

Systematic searches were conducted in PubMed and Embase for the period from January 2000 to January 2015 (see Fig. [1](#Fig1){ref-type="fig"} PRISMA flow diagram). Medical Subject Headings (MeSH) terms (PubMed) and 'explosion' terms (Embase) were used when available. Intervention-related search terms were difficult to define comprehensively, and were not covered by standard MeSH terms. The search string was therefore kept broad by including only terms describing statins and adherence. Studies describing patient-centered interventions were then identified manually at the post-search stage by screening titles/abstracts and/or full papers. The systematic searches were performed and screened by one author (SP) and then independently reviewed by a second author (MM-B).Fig. 1Flow diagram of searches and the study selection process

Study Inclusion Criteria {#Sec4}
------------------------

To be included, studies had to have a control arm and a post-intervention study period of at least 3 months. Prospective studies that were not randomized controlled trials (RCTs) and retrospective studies were included provided that controls were matched to the intervention group or, if unmatched controls were used, potential differences in patient characteristics between the intervention and control group (i.e. confounding) were adjusted for in the statistical analysis. Studies assessing the impact of interventions on measures of persistence (defined as the length of time between treatment initiation and the last dose \[[@CR19]\]) that did not also include measures of implementation (defined as the extent to which patients\' actual dosing corresponds to the prescribed dosing regimen \[[@CR19]\]) were not considered to measure adherence to statins for the purposes of this study and were therefore excluded. No other study quality criteria were applied.

Classification of Interventions {#Sec5}
-------------------------------

There is no accepted system for classifying interventions that target adherence to statins. We therefore adapted an approach used in a recent systematic review of interventions designed to enhance adherence to medication \[[@CR16]\]. Components of each intervention were classified into 1 of 5 main categories: cognitive education, behavioural counselling, medication reminder systems, adherence feedback and treatment simplification (see [Box 1](#Sec20){ref-type="sec"} in Appendix for detailed descriptions). Information on how interventions were delivered (face-to-face, telephone, mail, etc.), and whether they were delivered once or multiple times was also collected systematically. Categorization of interventions using this system was performed by two authors (MM-B and SP) and was then independently reviewed (and modified if necessary) by the remaining authors (MJK, MA and SB). When more than one intervention component was used in a study they were all captured as part of the intervention classification. In this way, interventions of varying complexity were represented. As with any review, our analysis is limited by what was reported in each study. We therefore cannot exclude the possibility that other intervention components were used in some studies but not reported.

Analysis of Data on Adherence to Statins {#Sec6}
----------------------------------------

Owing to considerable variation in study designs and the small number of studies using just one type of intervention, a meta-analysis of the data was not deemed appropriate. We therefore performed a narrative synthesis of the available data, consisting of two approaches. The first was a broad attempt to identify potential commonalities/differences in terms of interventions that significantly improve adherence to statins. This analysis (represented in Fig. [2](#Fig2){ref-type="fig"}) included all of the identified studies regardless of the adherence measure used. The second, more stringent analysis included only studies that used objective measures of adherence to statins such as prescription refills, pill counts or electronic monitoring systems and reported absolute differences in mean statin adherence levels \[medication possession ratio (MPR), proportion of days covered (PDC) or similar\]. This analysis (represented in Fig. [3](#Fig3){ref-type="fig"}) allowed the magnitude of the effects of different interventions on adherence to statins to be compared, albeit across fewer studies. The absolute mean difference in adherence to statins between an intervention and a control group was considered to be more transparent and clinically meaningful than differences in the proportion of adherent patients, which tend to be based on fairly arbitrary definitions of what constitutes adherence (e.g. MPR ≥ 0.80), and can underestimate or overestimate the impact of an intervention depending on how close patients already are to meeting the definition of adherence being used. For example, if most patients in a population have a mean MPR of 0.75 (i.e. currently taking 75 % of their doses), an intervention causing an absolute increase in mean adherence to medication of 6 % might shift a high proportion of patients from being defined as non-adherent to being defined as adherent, despite the questionable clinical significance of such a small effect.Fig. 2Combinations of components used in intervention groups (*n* = 34) to try to improve adherence to statins. *Each column* represents one intervention group. Intervention groups are ranked by the number of components involved. Components in each intervention group are illustrated by *blue boxes* (those in *yellow boxes* were applied to both the intervention group and the control group). *Pink boxes* highlight components that were not applied to all patients in the intervention group. Columns with interventions associated with a significant improvement in at least one measure of adherence are highlighted in *green*. *Letters in boxes* denote whether the component was used a single time (S) or multiple times (M).*Symbols* indicate who delivered the intervention: \*physician; ^†^pharmacist; and ^‡^nurse. *Roman numerals* indicate the number of 'other' intervention components used. The full text of the descriptions of the interventions used in each study in relation to how they were categorized is provided in Supplementary Table 1 (online)Fig. 3Studies reporting the mean proportion of days covered, medication possession ratio or similar parameter by intervention type. *1* Cognitive education, *2* behavioural counselling, *3* treatment simplification, *4* medication reminders, *5* adherence feedback, *A* face-to-face, *B* telephone (person), *C* hard copy materials, *D* telephone (automated), *E* other delivery components (*Roman numerals*indicate number of other delivery components), *S* single time, *M* multiple times. \*Statistically significant difference between control and intervention groups (*p* \< 0.05)

Results {#Sec7}
=======

Searches {#Sec8}
--------

Of 3613 combined search 'hits', 32 studies were identified that fulfilled the inclusion criteria \[[@CR20]--[@CR51]\]. The main reasons for exclusion were: irrelevant study topic, intervention directed towards healthcare professionals (rather than being patient-centered), intervention not sufficiently described and insufficient data on adherence to statins.

Study Characteristics {#Sec9}
---------------------

Most (20/32) of the included studies were conducted in North America \[[@CR21]--[@CR24], [@CR26]--[@CR30], [@CR32], [@CR36], [@CR37], [@CR43], [@CR45]--[@CR51]\], with 9 conducted in Europe \[[@CR20], [@CR31], [@CR34], [@CR35], [@CR38], [@CR39], [@CR41], [@CR42], [@CR44]\] and 3 in Asia \[[@CR25], [@CR33], [@CR40]\]. The median sample size for the intervention group was 202 (range: 15--29,042) and the median study duration was 12.0 months (range: 3 months--2 years). Many studies did not specify the reason for statin use in the included patients \[[@CR23], [@CR24], [@CR26], [@CR27], [@CR29]--[@CR31], [@CR38], [@CR41]--[@CR43], [@CR47], [@CR49], [@CR50]\]. Of those that did, half indicated that statins were prescribed for secondary CVD prevention \[[@CR20]--[@CR22], [@CR25], [@CR33], [@CR44]--[@CR46], [@CR48]\]. Other indications included primary hypercholesterolemia \[[@CR35]\], diabetes \[[@CR28], [@CR32]\] and elevated CVD risk \[[@CR36], [@CR37], [@CR39], [@CR51]\]. Five studies selected patients based on poor adherence to statin therapy \[[@CR24], [@CR26], [@CR31], [@CR36], [@CR38]\]. Two studies \[[@CR31], [@CR32]\] contained 2 intervention arms; hence, data from 34 intervention arms were included in the overall analysis. Study designs, patient characteristics, intervention types (based on the categorization used in Fig. [2](#Fig2){ref-type="fig"}) and the methods and raw data for all statin adherence (implementation and persistence) and cholesterol measures used in each study are summarized in Table [1](#Tab1){ref-type="table"}. The full published descriptions of the interventions used in each study and how they were categorized for inclusion in this review are provided in Supplementary Table 1 (online).Table 1Patient characteristics, intervention types (based on the categorization used in Fig. [2](#Fig2){ref-type="fig"}) and the methods and raw data for all adherence, persistence and cholesterol measures used in each studyRef \#Author\
Study designStatin treatment indication and/or status (country)*N*Mean age (y)^a^Female, %Follow-up (mo.)InterventionAdherence measure: intervention vs. control (significance)^b^Cholesterol measure: intervention vs. control (significance)^b^Implementation^c^Persistence^d^\[[@CR20]\]Yilmaz et al. (2005)\
RCTSecondary CVD prevention (Turkey)Int: 102\
Con: 10053 ± 8\
54 ± 1046\
49151A(S)Proportion taking statins continuously: 62.7 vs. 46.0 % (*p* = 0.017)Proportion still taking statins: 86.3 vs. 64.0 % (*p* \< 0.001)Proportion reaching LDL-C target of \<100 mg/dL: 64.7 vs. 43.0 % (*p* = 0.002)\[[@CR21]\]Faulkner et al. (2000)\
RCTSecondary CVD prevention (USA)Int: 15\
Con: 1564 ± 12\
61 ± 1247\
40241B(M) (int only)\
1A(S) (int and con)Proportion taking ≥80 % of pills based on pill counts: 63 vs. 39 % (*p* \< 0.05)NAMean change in LDL-C (mg/dL): −24.3 vs. −14.9 (*p* = 0.02)\[[@CR22]\]Alsabbagh et al. (2012)\
RCTSecondary CVD prevention; statin-naïve (Canada)Int: 46\
Con: 4820.4 ± 10.5\
63.5 ± 11.920\
23101B(S)Mean MPR: 0.87 vs. 0.90 (*p* = 0.058)Mean number of days between first and last refill: 381.2 vs. 403.0 (*p* = 0.39)NA\[[@CR23]\]Charland et al. (2014)\
Prospective; Matched controlsStatin naïve (USA)Int: 647\
Con: 64760 ± 12\
59 ± 1154\
5661C (*KIF6* genotype and associated treatment recommendation)Mean PDC: 0.77 vs. 0.68 (*p* \< 0.0001)\
Proportion with PDC ≥0.80: 63.4 vs. 45.0 % (*p* \< 0.001)Proportion still taking statins: 69.1 vs. 53.3 % (*p* \< 0.0001)NA\[[@CR24]\]Li et al. (2014)\
Prospective; Un-matched controls; Statistical analysis adjusted for patient characteristics that were significantly different between the intervention and control groupNon-adherent to statins (USA)Int: 58\
Con: 5963.6 ± 9\
63.6 ± 13.364\
76121E (*SLCO1B1\*5* genotype via website)Proportion self-reporting adherence at 12 mo.: 47 vs. 15 % (*p* \< 0.001)Proportion receiving new statin prescriptions by 4 mo.: 55 vs. 20 % (*p* \< 0.001)Mean change in LDL-C (mg/dL): −12.4 vs. 6.3 (*p* = 0.059)\[[@CR25]\]Peng et al. (2014)\
Cluster RCT 47 hospitals randomized to intervention or control groupSecondary CVD prevention (China)Int: 1795\
Con: 202661.5 ± 11.5\
60.4 ± 11.733\
31121E (unique password-protected website)Proportion of adherent patients (not defined): 56 vs. 33 % (*p* = 0.006)NANA\[[@CR26]\]Pringle et al. (2014)\
Patients were own controlsNon-adherent to statins (USA)Int: 29,042\
Con: 30,45459\
6057\
55122A(M)Mean PDC: 0.66 (before int) vs. 0.73 (after int) (*p* \< 0.001)\
Change from baseline in proportion with PDC ≥0.80: 7 vs. 2 % (*p* \< 0.001)NANA\[[@CR27]\]Taitel et al. (2012)\
Retrospective; Unmatched controls; Statistical analysis adjusted for co-variatesStatin naïve (USA)Int: 586\
Con: 51654.2 ± 12.4\
56.0 ± 12.254\
51122A(M)Mean MPR: 0.62 vs. 0.57 (*p* \< 0.01)\
Proportion with MPR ≥0.80: 40.9 vs. 33.7 % (*p* \< 0.01)Proportion persistent (\<60 consecutive days without any statin medication available): 43.9 vs. 38.2 % (*p* = 0.05)NA\[[@CR28]\]Thiebaud et al. (2008)\
Prospective; Matched controlsDiabetes (USA)Int: 2598\
Con: 259852.8\
51.178\
70122B(M)Mean MPR: 0.56 vs. 0.55 (*p* = 0.65)\
Proportion with MPR ≥0.80: 32.7 vs. 30.4 % (*p* = 0.23)NANA\[[@CR29]\]Johnson et al. (2006)\
RCTLLDs, not exclusively statins (USA)Int: 202\
Con: 202Range: 21--85 y50\
50182C(M)Mean Medication Adherence Scale (MAS) questionnaire score (higher score = better adherence): 3.4 vs. 3.0 (*p* \< 0.01)NANA\[[@CR30]\]Foreman et al. (2012)\
Retrospective; Matched-controls(USA)Int: 290\
Con: 29064.8 ± 11.9\
64.7 ± 13.747\
5484Mean PDC: 0.82 vs. 0.79 (*p* = 0.49)NANA\[[@CR31]\]Kooy et al. (2013)\
RCTNon-adherent to statins (Netherlands)Int 1: 123\
Int 2: 130\
Con: 12873.2 ± 5.8\
73.3 ± 6.6\
73.9 ± 6.557\
53\
58124 (int 1 and int 2)\
1A(S) (int 2)\
5 (int 2)Proportion with PDC ≥0.80 for int 1 vs. con: 72.4 vs. 64.8 % (*p* = 0.18)\
Proportion with PDC ≥0.80 for int 2 vs. con: 69.2 vs. 64.8 % (*p* = 0.55)Proportion who discontinued for int 1 vs. con: 5.7 vs. 9.4 % (*p* = 0.37)\
Proportion who discontinued for int 2 vs. con: 6.2 vs. 9.4 % (*p* = 0.37)NA\[[@CR32]\]Pladevall et al. (2014)\
RCTDiabetes (HbA~1c~ and LDL-C not at goal); LLDs, \~80 % taking statins (USA)Int 1: 569\
Int 2: 556\
Con: 56763.3 ± 10.9\
64.5 ± 10.5\
64.9 ± 11.547\
48\
5365 (int 1 and int 2)\
2A or B(M) (int 2)Mean MPR for int 1 vs. con: 0.70 vs. 0.70 (*p* = 0.952)\
Mean MPR for int 2 vs. con: 0.70 vs. 0.70 (*p* = 0.856)NAMean LDL-C (mg/dL) for int 1 vs. con: 87.3 vs. 89.0 (*p* = 0.38)\
Mean LDL-C (mg/dL) for int 2 vs. con: 85.6 vs. 86.0 (*p* = 0.08)\[[@CR33]\]Wu et al. (2012)\
RCTSecondary CVD prevention (China)Int: 55\
Con: 5573.2 ± 7.2\
75.7 ± 6.422\
18121A(M)\
1C(S)Proportion of patients who were compliant (not defined): 94.6 vs. 32.7 % (*p* = 0.016)NANA\[[@CR34]\]Nieuwkerk et al. (2012)\
RCT50 % primary CVD prevention; 50 % secondary CVD prevention; statin naïve (Netherlands)Int: 100\
Con: 10148.9 ± 1.2\
49.2 ± 1.341\
40181A(M)\
1E (risk-factor passport)Mean score based on number of days patients reported taking their medication in the past week (1 = no days; 5 = all 7 days): 4.9 vs. 4.6 (*p* \< 0.01)\
Mean score based on proportion of medication patients reported taking in the past month (1 = \< 30 %; 10 = 100 %): 9.4 vs. 8.9 (*p* \< 0.05)NAMean LDL-C (mg/dL) in primary prevention patients: 103 vs. 116 (*p* \< 0.05)\
Mean LDL-C (mg/dL) in secondary prevention patients: 97 vs. 92 (*p* = NS)\[[@CR35]\]Kardas et al. (2013)\
RCTPrimary hypercholesterolemia (Poland)Int: 107\
Con: 8959.5 ± 8.8\
59.7 ± 9.575\
76111A(M)\
2A(M)Mean MPR: 0.95 vs. 0.82 (*p* \< 0.05)Mean persistence (wks): 36.1 vs. 35.5 (*p* = NS)NA\[[@CR36]\]Ali et al. (2003)\
Patients were own controlsHigh CVD risk (age and ≥2 two other risk factors \[e.g. smoking, diabetes\]); non-adherent to LLDs (Canada)Int: 135 (own controls)Men aged \>45 y\
Women aged \>55 yNR61A(S) (int only)\
1B(M) (int only)\
1A(S) (int and con)\
1C(S) (int and con)Mean days between refills: 38 vs. 49 (*p* \< 0.001)\
Proportion renewing prescription within 6 days of 30-day renewal date: 56.0 % vs 40.7 % (*p* \< 0.05)NAMean LDL-C (mmol/L): 2.91 vs. 3.18 (*p* \< 0.01)\
Proportion reaching LDL-C target of \<3.4 mmol/L: 82.7 vs. 72.7 % (*p* \< 0.05)\
Proportion reaching LDL-C target of \<2.6 mmol/L: 35.5 vs. 28.2 % (*p* = NS)\[[@CR37]\]Guthrie et al. (2001)\
RCTHigh CVD risk (score ≥4 on First Heart Attack Risk Test); statin naïve (USA)Int: 10,355\
Con: 276557.9\
58.351\
5261B(M) (int only)\
1C(S) (int only)\
1A(S) (int and con)\
1C(M) (int and con)Proportion self-reporting adherence: 79.7 vs. 77.4 % (*p* = NS)NANA\[[@CR38]\]Stuurman-Bieze et al. (2013)\
Prospective; Unmatched historical control group; Statistical analysis adjusted for confoundersNon-adherent to LLDs, 98 % taking statins (Netherlands)Int: 502\
Con: 50061.3 ± 11.2\
60.9 ± 11.745\
42121F(M) (int only)\
2F(M) (int only)\
1A(M) (int and con)\
1C(S) (int and con)Proportion who discontinued or were non-adherent (MPR ≤0.80): 16.8 vs. 33.5 % (*p* \< 0.001)Proportion who discontinued: 13.6 vs. 25.9 % (*p* \< 0.001)NA\[[@CR39]\]Brath et al. (2013)\
RCTHigh CVD risk (≥2 of following: diabetes, high cholesterol and hypertension) (Austria)Int: 53 (own controls)69.4 ± 4.845134\
5Definition of adherence unclear (*p* = 0.23)NAMedian LDL-C (mg/dL): 80 vs. 87 (*p* = 0.06)\[[@CR40]\]Lee et al. (2004)\
Prospective; Patients assigned to intervention or control group based on appointment dateHyperlipidemia; statin naive (Hong Kong)Int: 26\
Con: 2449.2 ± 8.7\
50.9 ± 10.819\
1731A(M)\
1B(S)\
1C(S)Mean proportion of doses taken (assessed by direct questioning of patients): 82.1 vs. 60.5 % (*p* \< 0.05)\
Proportion taking ≥75 % of doses (assessed by direct questioning of patients): 76.9 vs. 41.7 % (*p* \< 0.01)NAMean change in LDL-C (mg/dL): --27.7 vs. --16.3 (*p* \< 0.05)\[[@CR41]\]Eussen et al. (2010)\
RCTStatin naïve (Netherlands)Int: 513\
Con: 50360.2 ± 10.9\
60.1 ± 11.353\
50121A(M)\
1C(S)\
1E (treatment goal wallet card)Median MPR: 1.0 vs. 0.99 (*p* = 0.14)Proportion who discontinued within 6 months of initiation: 11 vs. 16 % (*p* = 0.03)\
Proportion who discontinued within 12 months of initiation: 23 vs. 26 % (*p* = 0.21)NA\[[@CR42]\]Vrijens et al. (2006)\
RCT(Belgium)Int: 194\
Con: 19861.9 ± 9.9\
60.4 ± 10.245\
54121A(M)\
4\
5Median proportion of days taking statins (assessed by MEMS): 95.9 vs. 89.4 % (*p* \< 0.001)Proportion persistent (still taking statin after 300 days): 87 vs. 74 % (*p* = 0.002)NA\[[@CR43]\]Casebeer et al. (2009)\
Prospective; Matched controlsStatin naïve (USA)Int: 355\
Con: 19658NR41A(S)\
1C(M)\
2E (contract/pledge to confirm commitment to taking statins)Mean MPR: 0.68 vs. 0.57 (*p* \< 0.01)Proportion persistent (still refilling statin prescriptions): 67.8 vs. 57.8 % (*p* \< 0.01)NA\[[@CR44]\]Hedagaard et al. 2014\
RCTSecondary CVD prevention (Denmark)Int: 90\
Con: 8764 (range: 56--73)\
68 (range: 61--73)40\
38122A(S)\
2B(M)\
2C(M)Median MPR: 1.0 vs. 0.98 (*p* = 0.68)\
Proportion with MPR \<0.80: 22 vs. 21 % (*p* = 0.86)Proportion non-persistent (prescription not redeemed \<90 days after last prescription ran out): 20 vs. 18 % (*p* = NS)NA\[[@CR45]\]Ma et al. (2010)\
RCTSecondary CVD prevention (USA)Int: 351\
Con: 33860.4 ± 10.5\
60.3 ± 10.440\
40121A(S)\
1C(S)\
2B(M)\
2E (medication card)\
2E (pillbox)Mean adherence (total days of supply divided by total days between refills): 0.90 vs. 0.88 (*p* = 0.51)NAMean LDL-C (mg/dL): 94.5 vs. 97.8 (*p* = 0.24)\
Proportion reaching LDL-C target of \<100 mg/dL: 64.5 vs. 60.2 % (*p* = 0.29)\
Proportion reaching LDL-C target of \<70 mg/dL: 17.1 vs. 18.8 % (*p* = 0.66)\[[@CR46]\]Calvert et al. (2012)\
RCTSecondary CVD prevention (USA)Int: 51\
Con: 5063 (range: 54--71)\
62 (range: 52--70)34\
3961A(S)\
2C(S)\
2E (medication card)\
2E (adherence tip sheet)Proportion with PDC ≥0.75: 58 vs. 49 % (*p* = 0.34)\
Proportion self-reporting adherence: 98 vs. 98 % (*p* = 0.99)NANA\[[@CR47]\]Stacy et al. (2009)\
RCTStatin naïve (USA)Int: 253\
Con: 24454.6\
54.262\
6361C(S)\
1D(M)\
1E (website)\
2C(S)\
2D(M)Proportion with MPR ≥0.80: 47.0 vs. 38.9 % (*p* \< 0.1; considered statistically significant in this study)Proportion of patients still in possession of a statin: 70.4 vs. 60.7 % (*p* \< 0.05)NA\[[@CR48]\]Ho et al. (2014)\
RCTSecondary CVD prevention (USA)Int: 122\
Con: 11963.8 ± 9.3\
64.0 ± 8.572\
3121A(M)\
1B(optional)\
1D(M)\
2E (pillbox)\
3\
4Mean PDC: 0.95 vs. 0.84: (*p* \< 0.001)\
Proportion with PDC ≥0.80: 93.2 vs. 71.3 % (*p* \< 0.001)Mean LDL-C (mg/dL): 80 vs. 76 (*p* = 0.37)\
Mean reduction in LDL-C (mg/dL):\
--13 vs. --12 (*p* = 0.9)\
Proportion reaching LDL-C target of \<100 mg/dL: 72 vs. 83 % (*p* = 0.14)\[[@CR49]\]Goswami et al. (2013)\
RCT(USA)Int: 375\
Con: 12569.5 ± 12.3\
67.8 ± 10.641\
3261C (optional)\
2A(S)\
2C(S)\
2E (co-pay relief card-optional)Mean PDC: 0.82 vs. 0.81 (*p* = NS)\
Mean MPR: 0.82 vs. 0.79 (*p* = NS)\
Proportion with PDC ≥0.80: 71.6 vs 71.7 % (*p* = NS)\
Proportion with MPR ≥0.80: 76.8 vs. 75.5 % (*p* = NS)Mean persistence (days): 147.4 vs. 146.3 (*p* = NS)NA\[[@CR50]\]Holdford and Inocencio (2013)\
Prospective; Matched controlsTaking statins and ≥1 other medication type (USA)Int: 1281\
Con: 18,36168.4 ± 14.1100123\
2E(optional)Mean PDC: 0.84 vs. 0.62 (*p* \< 0.0001)\
Proportion with PDC ≥0.80: 76.2 vs 37.4 % (*p* \< 0.0001)Proportion non-persistent (not taking medication for ≥30 consecutive days): 41.6 vs. 72.5 % (*p* \< 0.0001)NA\[[@CR51]\]Evans et al. (2010)\
RCTHigh CVD risk (10-year Framingham risk score of ≥15%) (Canada)Int: 88\
Con: 8860.2 ± 10.2\
60.3 ± 10.117\
2261A, B, C or E (e-mail) (M) (int only)\
1A(S) (int and con)\
1C(S) (int and con)Proportion with PDC ≥0.80: 73.1 vs. 80.0 % (*p* = 0.33)Median LDL-C (mg/dL): 90.2 vs. 90.5 (*p* = 0.99)*1 *cognitive education;*2* behavioural counselling;*3 *treatment simplification;*4* medication reminders;*5* adherence feedback;*A* face-to-face;*B* telephone (person);*C* hard copy materials;*D* telephone (automated);*E* other delivery method;*S* single time;*M* multiple times; *int* intervention group;*con* control group*CVD* cardiovascular disease, *LDL-C* low-density lipoprotein cholesterol, *LLDs* lipid lowering drugs, *MEMS* Medication Event Monitoring System, *MPR* medication possession ratio, *PDC* proportion of days covered, *NA* not applicable, *NR* not reported^a^Mean ± standard deviation or standard error unless otherwise specified^b^Data are for intervention versus control unless otherwise specified^c^Defined as any data on the extent to which the patients actual dosing corresponds to the prescribed dosing regimen \[[@CR19]\]^d^Defined as any data on the length of time between treatment initiation and the last dose \[[@CR19]\]

Interventions and Statin Adherence (Implementation) {#Sec10}
---------------------------------------------------

The first parts of this section of the narrative synthesis (Sects. [3.3.1](#Sec11){ref-type="sec"}--[3.3.4](#Sec14){ref-type="sec"}) draw on data in Fig. [2](#Fig2){ref-type="fig"}, which presents all identified studies in order (from left to right) of the increasing number of intervention components they contained. In several of these studies the outcome measure for adherence to statins was not defined \[[@CR25], [@CR33], [@CR39]\], was described only as self-reported \[[@CR24], [@CR37]\], or used patient-reported questionnaires to estimate adherence to statins \[[@CR29], [@CR34]\], increasing the risk of bias in their reported results. Section [3.3.5](#Sec15){ref-type="sec"} draws on data in Fig. [3](#Fig3){ref-type="fig"}, which presents studies in the same order as Fig. [2](#Fig2){ref-type="fig"} but is limited to those using more reliable outcome measures of adherence to statins, and includes a quantitative component (absolute differences in mean statin adherence levels based on MPR, PDC or similar between intervention and control). Nevertheless, trends in either analysis may still be biased by substantial variation in other study characteristics (Table [1](#Tab1){ref-type="table"}), or be due to chance alone owing to the small number of available studies. While we have done our best to only report robust trends that (in the collective opinion of the authors) are unlikely to be artefactual, the reader should factor the above limitations into their interpretation of the results.

### Cognitive Education Interventions {#Sec11}

Cognitive education was the most frequently included intervention (Fig. [2](#Fig2){ref-type="fig"}). Only 3 studies (all RCTs) of 13 that used cognitive education as the only type of intervention did not report significantly improved adherence to statins compared with controls (Fig. [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}) \[[@CR22], [@CR41], [@CR51]\]. Most (8/10) of the studies that did report significantly improved adherence to statins with cognitive education only were RCTs or used a similarly unbiased prospective study design (randomization at hospital rather than patient level, intervention assigned based on appointment times, or patients used as own controls) (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR21], [@CR25], [@CR33], [@CR34], [@CR36], [@CR37], [@CR40]\]. The other two studies were prospective but not randomized: one used a matched control group, while the other used an un-matched control group but adjusted the statistical analysis for confounders (Table [1](#Tab1){ref-type="table"}) \[[@CR23], [@CR24]\].

There were seven RCTs (or similar) and one prospective study that included multiple, face-to-face, cognitive education sessions in their interventions (Table [1](#Tab1){ref-type="table"}) \[[@CR33]--[@CR35], [@CR38], [@CR40]--[@CR42], [@CR48]\]. All of these, except for Eussen et al \[[@CR41]\], reported a statistically significant improvement in adherence to statins (Fig. [2](#Fig2){ref-type="fig"}). Conversely, Eussen et al was the only one of 14 studies that did not report a statistically significant improvement in adherence to statins that included multiple, face-to-face, cognitive education sessions (Fig. [2](#Fig2){ref-type="fig"}). Importantly, Eussen et al reported very high mean adherence to statins (MPR of 99 %) in the control group (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR41]\], which would make it impossible to resolve an effect on adherence to statins even if one existed for this intervention.

There were nine studies that included a single, face-to-face, cognitive education session in their intervention, of which eight were RCTs or similar and one was a prospective study that included matched controls (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR21], [@CR31], [@CR36], [@CR37], [@CR43], [@CR45], [@CR46], [@CR51]\]. Of the five studies that reported a statistically significant improvement in adherence to statins, all except Yilmaz et al \[[@CR20]\] also included cognitive-education delivered multiple times via other methods (telephone, hard-copy materials or both), compared with none of the four studies that did not show improved adherence to statins (Fig. [2](#Fig2){ref-type="fig"}).

There were three studies that achieved a significant improvement in adherence to statins despite including only a single cognitive education session that was not delivered face-to-face (Fig. [2](#Fig2){ref-type="fig"}). Two of these studies (both prospective but not randomized) were unique in providing patients with test results for genetic polymorphisms as the sole intervention: one genetic variant was associated with an increased risk of myopathy with statin use and premature discontinuation (*SLCO1B1\*5* gene variant; genotyping information provided via a website) \[[@CR24]\] and the other variant had the potential to modulate reductions in coronary heart disease risk in statin users (*KIF6* gene variant; genotyping information provided in hard copy form along with genotype-guided treatment recommendations) \[[@CR23]\]. In one of these studies, adherence to statins was defined as self-reported, while the other reported adherence to statins as the mean PDC \[[@CR23], [@CR24]\]. The third study, by Peng and colleagues, did not define the outcome measure used to assess adherence to statins and employed a clustered (by hospital) randomized study design in which cognitive education materials were provided to the intervention group via a password-protected website \[[@CR25]\].

### Behavioural Counselling {#Sec12}

All three studies that used multiple, face-to-face behavioural counselling sessions significantly improved adherence to statins (mean MPR or PDC) relative to the control group (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR26], [@CR27], [@CR35]\]. Behavioural counselling consisted of motivational interviews in two of these studies (one retrospective and one where patients were their own controls) and was used alone \[[@CR26], [@CR27]\]. In the third study, an RCT, behavioural counselling consisted of patients being asked to adopt a new routine to remind them to take their medication, but was combined with multiple, face-to-face cognitive education sessions \[[@CR35]\]. Further patterns regarding the impact of behavioural counselling on adherence to statins were difficult to discern from the data in Fig. [2](#Fig2){ref-type="fig"}.

### Treatment Simplification {#Sec13}

Two studies included treatment simplification in their intervention, both of which reported a significant increase in adherence to statins (Fig. [2](#Fig2){ref-type="fig"}). One of these studies was an RCT that combined treatment simplification with multiple cognitive education sessions (face-to-face and via automated calls), a single behavioural counselling intervention (pillbox) and medication reminders \[[@CR48]\]. The other study, by Holdford et al, was a non-randomized prospective study that we classified as using treatment simplification plus an optional behavioural counselling component (pill box) \[[@CR50]\]. The appointment based medication synchronization (ABMS) intervention program described in the Holdford et al study also included the optional use of 'medication therapy management'. We could not confidently define this component for inclusion in our classification system, but it should be noted that descriptions of ABMS reported elsewhere indicate it may involve multiple face-to-face behavioural counselling and/or cognitive education sessions \[[@CR52]\]. Thus, ABMS may be a more complex intervention than we are able to report here based on our classification of the Holdford et al study.

### Medication Reminders and Adherence Feedback {#Sec14}

There were eight interventions across five RCTs and one retrospective study that were based on medication reminders and/or adherence feedback (Table [1](#Tab1){ref-type="table"}) \[[@CR30]--[@CR32], [@CR39], [@CR42], [@CR48]\]. All except one of these studies used the MPR, PDC or similar for their outcome measure of adherence to statins. None of the study arms that used only medication reminders and/or adherence feedback reported a significant impact on adherence to statins (Fig. [2](#Fig2){ref-type="fig"}). The only two studies using these intervention components that reported significantly increased mean adherence to statins combined them with multiple, face-to-face cognitive education sessions (Fig. [2](#Fig2){ref-type="fig"}).

### Comparative Effect Sizes for Different Interventions {#Sec15}

There were 17 intervention arms across 10 RCTs (or similar), 4 prospective studies and 2 retrospective studies that reported data on adherence to statins using similar, clinically meaningful measures (e.g. mean MPC or PDC) (Table [1](#Tab1){ref-type="table"}) \[[@CR22], [@CR23], [@CR26]--[@CR28], [@CR30], [@CR32], [@CR35], [@CR41]--[@CR45], [@CR48]--[@CR50]\]. Significantly increased mean adherence to statins relative to the control group was achieved in three of the seven studies that used only one intervention type: two used multiple, face-to-face motivational interviews \[+5 and +7 % points (both behavioural counselling)\] \[[@CR26], [@CR27]\] and one provided genotyping information for the *KIF6* gene variant \[+9 % points (cognitive education)\] \[[@CR23]\] (Fig. [3](#Fig3){ref-type="fig"}). These effect sizes are within the range observed in the five studies that combined more than one intervention type and achieved significantly improved adherence to statins (+7 to +22 % points) (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR35], [@CR42], [@CR43], [@CR48], [@CR50]\]. It is worth noting that the significant improvement in adherence to statins in three of the latter studies occurred despite having much higher mean adherence to statins in the control groups (range: 82--89 %) \[[@CR35], [@CR42], [@CR48]\] compared with the three studies that significantly improved adherence to statins using a single intervention type (range: 57--68 %) \[[@CR23], [@CR26], [@CR27]\] (Fig. [3](#Fig3){ref-type="fig"}). These were also the only studies (other than Eussen et al \[[@CR41]\]) in this sub-analysis to incorporate multiple, face-to-face cognitive education sessions into their intervention.

Interventions and Statin Adherence (Persistence) {#Sec16}
------------------------------------------------

Adherence to statins was measured in terms of persistence as well as implementation in nine RCTs, five prospective studies and one retrospective study (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR22]--[@CR24], [@CR27], [@CR31], [@CR35], [@CR38], [@CR41]--[@CR44], [@CR47], [@CR49], [@CR50]\]. Of 10 studies that measured both of these parameters and reported significantly improved statin implementation compared with controls only Kardas et al did not also report significantly improved persistence (Table [1](#Tab1){ref-type="table"}) \[[@CR35]\]. Conversely, of five studies that reported no significant effect of the intervention on statin implementation, only Eussen et al reported any significant effect on persistence \[[@CR41]\].

Impact of Improved adherence to Statins on Cholesterol Measures {#Sec17}
---------------------------------------------------------------

The impact of interventions on cholesterol measures (mean LDL--C, LDL--C change from baseline, proportion reaching target LDL--C levels) was reported in addition to their impact on adherence to statins in nine RCTs (or similar) and two prospective studies (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR21], [@CR24], [@CR32], [@CR34], [@CR36], [@CR39], [@CR40], [@CR45], [@CR48], [@CR51]\]. Of the seven studies reporting improved adherence to statins with their intervention, five also reported a significant improvement in at least one cholesterol measure (Table [1](#Tab1){ref-type="table"}). All four studies reporting no significant improvement in adherence to statins also reported no significant improvement in any cholesterol measure.

Discussion {#Sec18}
==========

There is growing interest in establishing which interventions can improve adherence to statins, as evidenced by the fact that most \[22/32 (69 %)\] of the studies we identified were published in 2010 or later (the search string was designed to capture any articles published since 2000). A number of high-quality reviews have attempted to assess the impact of interventions on adherence to medication \[[@CR16]--[@CR18]\]. However, to our knowledge, we are the first to undertake a systematic search for and analysis of studies addressing this problem in relation to statin use.

We categorized interventions according to their component parts, who delivered them and how they were delivered, in an attempt to identify those that genuinely improve adherence to statins. The main limitation of this approach (others are discussed below) is that most interventions assessed in the literature include more than one type of component, making it difficult to know what contribution individual components are adding to observed improvements in adherence to statins. For this reason, and because of considerable variation in study designs, meta-analysis was not deemed appropriate. Despite these limitations, some interesting trends were observed in our narrative synthesis of the data, from which we believe some cautious inferences can be drawn.

Our findings suggest that face-to-face cognitive education interventions are effective at improving patient adherence, particularly if delivered more than once. Notable exceptions to this were two studies that provided patients with the results of pharmacogenetic tests that were potentially relevant to the efficacy or adverse effects of their statin treatment \[[@CR23], [@CR24]\]. These results were delivered only once by mail or via a website and yet significantly improved adherence to statins. It is possible that the benefit of this form of educational material lies in its highly personalized nature, directly linking the treatment to the individual and thus providing motivation for patients to modify medication adherence behaviours.

Although only a few studies were available that used medication reminders or adherence feedback, the data were consistent in showing that these intervention components did not have a significant impact on adherence to statins. The only study that used these interventions and significantly improved adherence to statins also used a face-to-face cognitive education component delivered multiple times, which was the most consistently successful intervention type identified in this review and could therefore be responsible for the observed improvement in adherence to statins in this study \[[@CR42]\].

It was also noted that studies using multiple intervention types improved adherence to statins despite mean adherence levels that were generally higher in their control groups than in the control groups of studies that only used one type of intervention. It may be that combining different intervention types is a more effective strategy for improving adherence to statins in populations that already have a relatively high level of statin adherence, although the use of multiple, face-to-face, cognitive education sessions was also a common feature of these studies and could thus have constituted the main 'active' component.

Measuring medication adherence accurately is extremely difficult with currently available methods. Several approaches were used in the studies we identified, most of which were indirect and thus questionable in terms of their reliability. The most common method involved monitoring prescription refills, but this merely measures medication possession, not consumption. Indeed, many patients may feel obliged to refill their prescriptions according to their doctor's instructions, regardless of whether they take the medication. More direct methods of assessing adherence to medication, such as medication event monitoring systems (MEMS), which electronically monitor when medication bottles are opened, and biomarker detection systems, which directly assess medication consumption (e.g. by measuring drug metabolites in urine or plasma), may be better options. However, MEMS is very costly (used in only one of our identified studies \[[@CR42]\]), and assessment of biomarkers of adherence to medication may impose a substantial burden on the patient. It is possible, however, that these issues may be overcome in the future. For example, refinement of MEMS technology and its incorporation into the 'Internet of things' may enhance affordability, while novel sensor technology and wearables have the potential to increase the practicality of biomarker detection.

Another significant challenge when quantifying the impact of different interventions on adherence to medication is the lack of standardization in terms of how it is compared. In our first analysis we looked for broad, over-reaching patterns in the data that held across different studies in spite of variation in how adherence was measured, or other differences in study characteristics such as study design and patient characteristics. In our second analysis, we compared only studies that assessed the absolute change in adherence to statins (based on MPR, PDC or similar), rather than the proportion of patients shifted towards 'adherent behaviour' by interventions. We made this choice because measuring adherent behaviour means that arbitrary thresholds must be defined and this may give an inaccurate impression of the impact of an intervention. Indeed, several studies included in this review reported both absolute change in adherence to statins and the changes in the proportion of patients defined as being adherent to statins, with the latter giving values approximately twice that of the absolute change. The medical relevance of any medication adherence measure can of course be debated, but to help to quantify and compare different interventions, we recommend absolute difference in adherence to medication as the most transparent and easily interpretable measure.

The exact content of the interventions used in several of the included studies could not be easily quantified or categorized, often because it is not practical to publish full details of the materials used to deliver interventions, especially for cognitive education and behavioural counselling approaches (e.g. interview guides, educational pamphlets, videos). Thus, differences between studies that impact on the relative success of their interventions have almost certainly been missed by our broad (though necessarily practical) method of categorization. Furthermore, distinguishing between cognitive education and behavioural counselling approaches can often be conceptually difficult and is prone to subjective interpretation. Nevertheless, any such misclassification would not be likely to be systematically biased in any particular direction and therefore would be unlikely to influence the broad and tentative conclusions of this review.

To our knowledge, none of the interventions identified in this review have been broadly implemented in general healthcare practices. This is most likely to be due to the poor cost effectiveness associated with the most effective interventions, namely cognitive education (and potentially behavioural counselling) delivered via multiple, face-to-face sessions. These approaches are extremely resource intensive (for both patients and providers), requiring substantial time, planning and travel, and appear to have only modest effects. Indeed, the cost of the intervention in the study by Ho and colleagues (the only study providing such data) was estimated at US\$360 per patient-year, but yielded a mean increase in the proportion of days covered by statins of only 11 percentage points \[[@CR48]\]. The challenge is therefore to find alternatives that can offer similar or enhanced benefits compared with face-to-face consultations but that can be maintained on a long-term basis across the population at an affordable cost. One such alternative could be the use of mobile health (mHealth), which uses smart phone or tablet applications and thus has the potential to reach many patients at a relatively low cost. Compared with other approaches, mHealth has the potential for greater personalization, which appears to be a key factor in effective interventions. A recent review by Hamine et al found that adherence to medication was improved in 56 % of RCTs that used mHealth approaches in patients with chronic diseases \[[@CR53]\].

Conclusion {#Sec19}
==========

In this narrative synthesis of 32 systematically identified studies we found consistent evidence that cognitive education (and possibly also behavioural counselling) delivered face-to-face multiple times improves adherence to statins. Although absolute increases in mean adherence to statins were fairly modest for these interventions (+7 to +22 %), they did tend to be associated with improvements in cholesterol measures. However, these types of interventions are extremely resource intensive and thus are often too costly to apply to the general population. Modern communication and sensor technology in the form of mHealth have recently been used to improve adherence to other chronic disease medications. The lack of studies using these applications to improve adherence to statins suggests that this promising approach has not yet been properly investigated in this therapy area. Given the successful application of mHealth elsewhere, there is reason to be optimistic that the challenge of improving general adherence to statins can be met. Research in this area should be a priority.
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Appendix {#Sec20}
========

Box 1Definitions of the intervention classifications*Cognitive education interventions* are based on the concept that patients who are educated about their condition (e.g. about dyslipidemias, the link between cholesterol and CVD, the role of modifiable and non-modifiable risk factors) and its treatment (e.g. mechanism of action of statins, side effects, importance of adherence) will be more empowered, motivated and likely to adhere. Educational initiatives included sessions conducted individually or in a group setting (e.g. lectures), as well as didactic and interactive approaches (e.g. risk-factor passport, treatment goal wallet)*Behavioural counselling interventions* include strategies aimed at changing and/or reinforcing behaviour to achieve a positive impact on adherence. Interventions in this category included: motivational interviewing (note: this may include cognitive education interventions, but as part of a wider strategy aimed at increasing motivation); skill building by a health professional (e.g. teaching patients to use problem-solving skills to address adherence issues); and use of pillboxes, calendars, adherence tip sheets, or other steps to remind the patient to take their medication (e.g. associating taking medication with a routine activity)*Medication reminder systems* use a technical device to remind patients when it is time to take their medication (e.g. text messages, 'beep card')*Adherence feedback* provides patients with feedback on their adherence levels (e.g. recorded by electronic monitoring systems, prescription refill data) so that they have the opportunity to modify their behaviour accordingly*Treatment simplification* consists of changes in dose regimens or formulations, or synchronization of several medications to make it easier for patients to take their medication. This, in theory, should facilitate adherence
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